Targeted treatment for conjunctival melanoma harboring a BRAF mutation could be considered since the genetic profile is similar to that of cutaneous melanoma in which BRAF/MEK inhibitors are used. Here, MAP2K7 is linked to malignant conjunctival melanoma.